Cetirizine or Diphenhydramine Before Infusions for People With Multiple Sclerosis
Compares two allergy medicines taken before infusion treatment in adults with multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project
Key facts
- Where
- Boca Raton, United StatesSee the site
- Phase
- Phase 3
Where in United States
- UHealth Boca RatonBoca Raton, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Miami
- Trial code
- NCT07472413
- Record updated
- 2 October 2026
- Original description
The purpose of this study is to assess and compare how well multiple sclerosis (MS) patients tolerate cetirizine versus diphenhydramine as a pre-medication before receiving anti-CD20 infusion therapy of ocrelizumab, ublituximab or rituximab. The study will also compare the safety of cetirizine versus diphenhydramine as a pre-medication for preventing infusion reactions in MS patients receiving anti-CD20 infusion therapy.Read full original descriptionShow less
Cetirizine Versus Diphenhydramine as a Pre-medication: Tolerability and Safety in Patients With MS Receiving Anti-Cluster of Differentiation 20 (CD20) Infusion Therapy
The purpose of this study is to assess and compare how well multiple sclerosis (MS) patients tolerate cetirizine versus diphenhydramine as a pre-medication before receiving anti-CD20 infusion therapy of ocrelizumab, ublituximab or rituximab. The study will also compare the safety of cetirizine versus diphenhydramine as a pre-medication for preventing infusion reactions in MS patients receiving anti-CD20 infusion therapy.
Inclusion: Ages ≥18 years; Able to read and speak in English or Spanish; Able to and willing to give informed consent; Diagnosis of Multiple Sclerosis (MS); Patients starting or currently receiving ocrelizumab, ublituximab, rituximab.
Exclusion: Patients with prior hypersensitivity reactions on additional preventative measures (e.g. H1 and H2/proton-pump inhibitor (PPI) the night prior to the infusion due to history of reactions); Known hypersensitivity to cetirizine or any of its ingredients or hydroxyzine; Moderate or severe renal impairment (creatinine clearance or 11-31 mL/min or worse); Patients younger than 18 years of age; Adults unable or unwilling to consent; Pregnant women.